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To describe the optical coherence tomography (OCT) and electrophysiological changes in a case of closantel toxicity.
A 25-year-old patient presented with sudden painless defective vision following intake of closantel. Visual acuity (VA) was counting fingers at 5 m in both eyes (BE). OCT revealed disruption of outer retinal layers and electroretinogram (ERG) and visual evoked potential (VEP) were subnormal in BE. The patient was treated with systemic corticosteroids, after which his VA improved to 6/9, OCT revealed preservation of central outer retinal layers, and ERG and VEP responses improved in BE. This is the first case report of successful treatment with systemic steroids for closantel-related reversible blindness.
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Closantel is a halogenated salicylanilide used for the management of parasitic infestation in animals and is contraindicated in humans. [1] Overdose of closantel has been reported to be neurotoxic, ophthalmotoxic, and hepatotoxic in animals. Closantel toxicity is having no specific antidote and the reports in humans are limited. [2] In this study, we describe the reversible blindness and document optical coherence tomography (OCT) and electrophysiological findings in a patient of accidental ingestion of closantel.
Case Report
A 25-year-old farmer presented with sudden painless defective vision in BE for 3 days. He did not give any other systemic illness and his systemic examination including central nervous system and per-abdominal examination was normal. He had ingested closantel oral solution (Clositel, manufactured by Ratnamani Healthcare PVT., Ltd., Gujarat, India, meant for treatment of parasitic infestation of cattle and sheep), mistaking it for cough syrup. The ingested dose of closantel was 2250 mg (15 ml, each ml containing 150 mg). His visual acuity (VA) was counting fingers at 5 m in BE. There was no relative afferent pupillary defect, ocular movements were full, and rest anterior segments were normal. Visual fields were not recordable in BE. Intraocular pressure of both the eyes was 16 mm Hg. Fundus examination showed mild temporal optic disc pallor [ Fig. 1a and b] and FFA showed stippled hyperfluorescence [ Fig. 1c and d] in BE. Fundus autofluorescence of BE showed normal macula in both the eyes [ Fig. 1e and f]. OCT of macula of BE revealed gross disruption of outer retinal layers, namely external limiting membrane, myoid zone, ellipsoid zone, outer segment of photoreceptors, interdigitation zone, and retinal pigment epithelium [ Fig. 2a and b] . Electrophysiological tests were done according to standard protocols recommended by the International Society for Clinical Electrophysiology of Vision. [3, 4] ERG of BE showed severe decrease in both rod and cone responses [ Fig. 3 Panel a]. Flash VEP was not recordable. Pattern VEP showed decreased amplitude in BE and delayed P100 latency in the right eye (RE), suggestive of optic nerve dysfunction in RE [ Fig. 4 Panel a]. The patient was treated with intravenous injection of methyl prednisolone 1 g (once) daily for 3 days followed by oral prednisolone 40 mg (once daily and tapered. At one month follow-up, his VA improved to 6/9 in BE. OCT revealed preservation of central outer retinal layers with parafoveal loss of IS-OS junction [ Fig. 2c 
Discussion
Closantel is prescribed for the treatment and control of both nematodes and liver fluke infestations in sheep and cattle and is effective against Haemonchus contortus, Fasciola hepatica, and Oestrus ovis larvae. [5] Closantel acts via energy metabolism pathway by uncoupling oxidative phosphorylation in liver flukes. [1] Following oral intake in animals, the peak plasma concentration reaches in 8-48 h with elimination half-life of 2 to 3 weeks. Closantel is poorly metabolized and its tissue distribution is limited (distribution volume <0.15 L/kg) by its strong protein binding (>99.9% to plasma albumin). [6] Its pharmacokinetics in humans are unknown. [2] In closantel toxicity, the pathological lesions described in animals include narrowing of intracanalicular optic nerve and optic disc atrophy. [1, 5] The histopathologic changes include severe myelinic edema, vacuolation, wallerian degeneration, reactive astrocytosis and spongiform degeneration in the brain, and photoreceptor layer loss, and outer and inner nuclear layer damage in retina. [5] Till date five publications (17 cases in total) of closantel toxicity in humans have been reported in English literature, out of which only one case, i.e. the one reported by Koziolek et al. [2] was successfully treated (by plasmapheresis) and had good visual outcome. [1, 2, [7] [8] [9] An outbreak of closantel toxicity was first described in Lithuania in 1993, where 11 women were wrongly prescribed closantel mistaking it to be a gynecological drug. [7] In the current case, the pretreatment OCT scan of macula of BE was suggestive of severe disruption of photoreceptor layers and outer and inner nuclear layers. The ERG was suggestive of decreased response of the rods and the cones in BE. The VEP was suggestive of decreased amplitude and delayed latency in the RE. The exact mechanism of better visual outcome after treatment with systemic steroids was not well understood. However, with the knowledge that the peak plasma concentration in animals is described to be 8-48 h and presumably some inflammatory mediators result in toxic damage caused by closantel, the proposed explanation may be the early initiation of steroid treatment (on third day) resulted in limited exposure to the inflammatory and toxic effects of the drug. In all other case reports, the treatment was started much later. Tabatabaei et al. [1] has also described treatment with systemic steroids similar to the regimen in the current case. However, the poor outcome in their case may be ascribed to the late presentation of the patient (10 days). The dose consumed in the current case is 2250 mg, which is larger than the cases reported previously (1500 mg in the case reported by Tabatabaei et al. [1] and 1800 mg in the case reported by Koziolek et al. [2] ), thus ruling out the possibility of smaller dose of the drug being the reason for better visual outcome. The documentation of preservation of subfoveal IS-OS junction in OCT and improved ERG and VEP responses support the posttreatment better visual outcome. Flash VEP showed improved responses, and there was no changes in pattern VEP. This could probably suggest that the cones are first to improve and long term follow-up is needed to document for the improvement of the rods. Probably closantel affected the phosphorylation of rhodopsin during phototransduction in outer segment of photoreceptors. We do acknowledge that multifocal ERG would have been a better modality to document the visual outcome. This is the first case report of successful treatment with systemic steroids for closantel-related reversible blindness, which is known to have poor visual outcomes. Public health awareness about the toxicity of the drug is warranted. Prompt treatment with systemic steroids may be beneficial in cases presenting early.
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C o m m e n t a r y : C l o s a n t e l -A lesser-known evil
Closantel is an antiparasitic agent routinely used in veterinary practice against some parasites of livestock. It is not used against agricultural and household pests. Recently, it has been discovered that closantel also acts against Onchocerca volvulus, a filarial nematode causing river blindness in humans. [1] Closantel belongs to the chemical class of the salicylanilides, which acts as an uncoupler of oxidative phosphorylation in the cell mitochondria and disturbs ATP production. This impairs the parasite's motility and probably other processes as well. Closantel also disturbs the liquid and ion transport mechanisms in the parasite's membranes.
Closantel is a narrow-spectrum anti-helminthic effective against a few roundworms (mainly blood-sucking species), against flukes (e.g., Fasciola hepatica) and also against certain myiasis. It is ineffective against tapeworms or most external parasites. It is not used in swine, poultry, horses, or pets. It is used moderately in ruminants both as an injectable or a drench, often mixed with other anti-helminthics.
After oral administration, closantel is readily absorbed into the bloodstream. Four days after treatment up to 60% of the injected and 30% of the drenched closantel is absorbed to blood. In the blood, >99% of the unchanged closantel binds strongly to plasma albumins. Peak plasma levels are reached between 10 and 48 h after administration, both after oral or intramuscular administration. Half-life in plasma is 3 to 4 weeks. Owing to the strong binding to plasma albumins, closantel residues in the tissues are rather low. Closantel is poorly metabolized. Approximately, 80% of the administered dose is excreted through the feces, of which >98% in the parent molecule form. Excretion 48 h after oral administration reaches ~45% of the administered dose, but only ~10% after intramuscular injection. Excretion half-life in the organism is 2 to 3 weeks. In dairy cows, about 1% of the administered dose is excreted unchanged through the milk.
The routinely used safe-dose for the anti-helminthic action of closantel varies from 3 to 10 mg/kg depending upon the type of parasite and the animal affected. The established lethal dose limit for oral closantel in rats is 342 mg/kg, and for subcutaneous administration is 67 mg/kg of the active ingredient. Closantel intoxication has been reported in animals such as sheep, cattle, goats, and dogs. [2] [3] [4] [5] Closantel intoxication often presents with neurological and ocular features. The central nervous system, retina, and optic nerve are commonly affected. Histopathological changes noted are spongiosis in the brain white matter and spinal cord. These changes are symmetrical and affect periventricular white matter, optic radiation, brain stem, thalamic nuclei, and cerebellar peduncles. The induced histopathological changes in optic nerve following closantel overdosage include significant spongiform change, edema, and myelin vacuolization resulting in optic disc atrophy. [6] This results in edema in the intracanalicular portion of the optic nerve, which being in the osseous part gets compressed, resulting loss of myelinated axons. [6] In retina, there is destruction and apoptosis of the outer retinal layers, especially photoreceptors.
The most frequent symptoms following closantel intoxication include loss of appetite, ataxia or uncoordinated movements, weakness, visual disturbances, and blindness. Other symptoms reported in sheep include depression, prostration, colic, reduced skin sensitivity, opisthotonos, nystagmus, mydriasis, loss of pupillary reflex, and blindness. Mortalities can also happen. The use of closantel in humans and milk-producing animals is strongly avoided. However, accidental ingestion of closantel leading to overdose and adverse effects in humans has been reported in literature. [7] [8] [9] [10] In humans, ocular symptoms following closantel overdosage range from sudden onset blurring of vision to total blindness. The onset of symptoms has been reported to occur from as early as 3 days to 22 years following closantel intake. [9, 10] Depending upon the severity of damage, ocular features show optic nerve involvement ranging from blurring of disc margins and disc edema in acute stage to optic atrophy in the late stages. There is outer retinal layer thinning with spicule like hyper-pigmentation owing to the involvement of photoreceptor and retinal pigment epithelium layer. Destruction in outer retinal layers and visual pathway leads to changes in electroretinography and visual evoked potential (VEP) test. On electro-retinography, there is a reduction in both a-and b-wave amplitudes, whereas VEP shows a reduction in amplitude and delay in latency. The effects of closantel intoxication are often permanent and irreversible. There is no specific antidote for closantel. Treatment consists of supportive and symptomatic measures. Partial visual recovery with plasma exchange has
